Cryoport FY 2023 revenue $233.3M (-2% YoY); net loss $99.6M; guides FY 2024 $242-252M

Cryoport, Inc.

Q4 revenue $57.3M (-5% YoY); FY revenue $233.3M (-2% YoY). Services grew 8% but product fell 14%.
Net loss for FY $99.6M includes $49.6M goodwill impairment; adjusted EBITDA negative $8.3M vs positive $13.9M prior year.
Commercial Cell & Gene therapy revenue up 33% YoY; BioStorage/BioServices up 45%; record 675 clinical trials supported.
FY 2024 revenue guidance $242-252M; expects progressive growth.
Cash, equivalents & short-term investments $456.8M; $36M remaining under $100M repurchase program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cryoport, Inc. reported the fiscal year ended December 31, 2023 results: revenue $233.3 million.

Period: the fiscal year ended December 31, 2023
Revenue: $233.3 million
Result: reported results

Exact text from the filing

Today we reported full year results including total revenue of $233.3 million for the fiscal year ended December 31, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cryoport, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $57.3 million.

Period: the fourth quarter ended December 31, 2023
Revenue: $57.3 million
Result: reported results

Exact text from the filing

Total revenue for Q4 2023 was $57.3 million compared to $60.4 million for Q4 2022

View on SEC.gov

Browse all earnings releases →

Cryoport, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-033491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.